Received Jul 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
flu like symptoms; malaise; ache/ Pain; This non-serious case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On 27-JUN-2025, the patient received the 1st dose of Shingrix. In JUN-2025, 12 hrs after receiving Shingrix, the patient experienced influenza-like symptoms (Verbatim: flu-like symptoms), malaise (Verbatim: malaise) and pain (Verbatim: ache/ Pain). The outcome of the influenza-like symptoms, malaise and pain were unknown. It was unknown if the reporter considered the influenza-like symptoms, malaise and pain to be related to Shingrix. It was unknown if the company considered the influenza-like symptoms, malaise and pain to be related to Shingrix. Additional Information: GSK receipt date: 15-JUL-2025 The reporter was the patient who received her first dose of Shingrix and 12 hours after the dose, she experienced flu like symptoms, malaise, aches and pain. She wished to remain anonymous.